Medicare Enrolled

Dr. Julie Geary, MD

Internal Medicine · Newburyport, MA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
255 LOW ST STE 102, Newburyport, MA 01950
9784633197
In practice since 2006 (20 years)
NPI: 1285691238 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Geary from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Geary? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Geary

Dr. Julie Geary is an internal medicine specialist in Newburyport, MA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Geary performed 11,301 Medicare services across 826 unique beneficiaries.

Between the years covered by Open Payments, Dr. Geary received a total of $6,153 from 39 pharmaceutical and/or device companies across 431 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Geary is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 1% volume in MA $6,153 industry payments

Medicare Practice Summary

Medicare Utilization ↗
11,301
Medicare services
Top 1% in MA for internal medicine
826
Unique beneficiaries
$25
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~565 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Denosumab injection (Prolia/Xgeva) 10,140 $18 $35
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
831 $93 $420
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
170 $11 $70
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
68 $67 $300
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
54 $117 $525
Telephone medical discussion, 11-20 minutes
A phone conversation with a physician lasting between 11 and 20 minutes.
38 $66 $250
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$6,153
Total received (2018-2024)
Avg $879/year across 7 years
Top 15% in MA for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
39
Companies
431
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,153 (100.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,064
2023
$1,014
2022
$939
2021
$689
2020
$624
2019
$945
2018
$879

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$231
Novo Nordisk Inc
$161
Lilly USA, LLC
$156
ABBVIE INC.
$133
Boehringer Ingelheim Pharmaceuticals, Inc.
$91
Bayer Healthcare Pharmaceuticals Inc.
$51
Xeris Pharmaceuticals, Inc.
$41
IBSA Pharma Inc.
$38
Astellas Pharma US Inc
$31
SANOFI-AVENTIS U.S. LLC
$30
CeQur Corporation
$26
Tandem Diabetes Care, Inc.
$25
Currax Pharmaceuticals LLC
$17
Abbott Laboratories
$17
Kyowa Kirin, Inc.
$16
Top 3 companies account for 51.6% of 2024 payments
All-time payments by company (2018-2024) ›
Novo Nordisk Inc
$1,250
Lilly USA, LLC
$756
Amgen Inc.
$737
SANOFI-AVENTIS U.S. LLC
$384
AstraZeneca Pharmaceuticals LP
$335
Boehringer Ingelheim Pharmaceuticals, Inc.
$332
Xeris Pharmaceuticals, Inc.
$196
IBSA Pharma Inc.
$187
Senseonics, Incorporated
$173
ABBVIE INC.
$165
Janssen Pharmaceuticals, Inc
$130
Bayer Healthcare Pharmaceuticals Inc.
$120
AbbVie, Inc.
$119
Horizon Therapeutics plc
$119
Merck Sharp & Dohme Corporation
$105
Abbott Laboratories
$103
Medtronic MiniMed, Inc.
$90
Tandem Diabetes Care, Inc.
$81
AbbVie Inc.
$78
Kyowa Kirin, Inc.
$65
CeQur Corporation
$60
Bayer HealthCare Pharmaceuticals Inc.
$57
Ultragenyx Pharmaceutical Inc.
$42
Dexcom, Inc.
$42
Mannkind Corporation
$41
MannKind Corporation
$41
Alexion Pharmaceuticals, Inc.
$40
Nevro Corp.
$36
Medtronic, Inc.
$36
Radius Health, Inc.
$32
Insulet Corporation
$32
Astellas Pharma US Inc
$31
LifeScan, Inc.
$27
GRT US Holding, Inc.
$21
Valeritas, Inc.
$21
Esperion Therapeutics, Inc.
$19
Companion Medical, Inc.
$19
Currax Pharmaceuticals LLC
$17
Corcept Therapeutics
$15
Top 3 companies account for 44.6% of all-time payments
Associated products mentioned in payments ›
AFREZZA · BAQSIMI · BASAGLAR · CLOSUREFAST · CONTRAVE · CeQur Simplicity · Crysvita · Dexcom G6 Transmitter · EVENITY · Eversense · FARXIGA · FREESTYLE LIBRE · FREESTYLE LIBRE 2 · FREESTYLE LIBRE 3 · FreeStyle Libre · FreeStyle Libre 2 · FreeStyle Libre blood glucose Flash Monitoring System · GVOKE HYPOPEN · GVOKE PFS · HUMULIN R 500 · INVOKANA · InPen · JANUVIA · JARDIANCE · Kerendia · Korlym · LICART · LYUMJEV · MOUNJARO · Minimed 530G · Minimed 670G System · NEXLETOL · OT Verio Reflect "One Touch Meter and Strips" · Omnia · Omnipod · Ozempic · Prolia · Qutenza · RECORLEV · RYBELSUS · Repatha · Rybelsus · SOLIQUA · SOLIQUA 100/33 · SYNJARDY · SYNTHROID · Saxenda · Strensiq · Synthroid · TEPEZZA · TOUJEO · TRULICITY · TZIELD · Tirosint · Tresiba · V-GO · Veozah · Wegovy · XARELTO · Xultophy 100/3.6 · ZEPBOUND · t-slim insulin pump · t:slim X2 Insulin Pump with Control-IQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for an internal medicine specialist in Newburyport?
Compare internal medicine physicians in the Newburyport area by procedure volume, costs, and industry payment transparency.
Browse internal medicine physicians nearby

Geographic Context

Internal medicine physicians within 10 mi
552
Per 100K population
68.4
County median income
$99,431
Nearest hospital
ANNA JAQUES HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Geary is a mixed practice specialist, with above-average Medicare volume (top 1% in MA), with low-engagement industry engagement in the top 15% of MA peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Geary experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Geary performed 10,140 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Geary receive payments from pharmaceutical companies?
Yes. Dr. Geary received a total of $6,153 from 39 companies across 431 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Geary's costs compare to other internal medicine physicians in Newburyport?
Dr. Geary's average Medicare payment per service is $25. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Geary) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →